LGVN

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies based on Medicinal Signaling Cells (MSCs). The company's lead product candidate targets aging-related and life-threatening conditions including Alzheimer's disease, aging frailty, and acute respiratory distress syndrome. Longeveron's research focuses on harnessing the body's natural healing mechanisms to address diseases with significant unmet medical needs.